Needham Reiterates Buy Rating on Revolution Medicines, Inc.
Needham has reiterated its buy rating for Revolution Medicines, Inc. with a price target of $235, a 25.48% upside from the current price.
Key Points
- On June 29, 2026, Needham reiterated its buy rating for Revolution Medicines, Inc. (RVMD) with a price target of $235.
- Needham's $235 price target implies 25.48% upside from Revolution Medicines, Inc.'s ($RVMD) current $187.28 share price.
- Shares of RVMD traded near $182.08 on Monday with a market cap of approximately $38.7 billion and a 52-week range of $34.00 to $184.39.
- Insider activities included CFO Anders Jack's planned sale and purchase of shares, and analyst consensus remains strong buy with a target mean price of $188.57.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Needham reiterated its buy rating for Revolution Medicines, Inc. (NasdaqGS: RVMD) on June 29, 2026, maintaining a price target of $235. The analyst behind this decision, Ami Fadia, continues to see potential in the company's stock. On the same day, shares of Revolution Medicines traded near $182.08.
Needham vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Revolution Medicines, Inc. Stock Down 9.9%
Shares of Revolution Medicines, Inc. traded around $182.08 on Monday. The company, which is part of the biotechnology sector, has a market cap of approximately $38.7 billion. It is not currently profitable and has no meaningful P/E ratio. The stock's 52-week range is $34.00 to $184.39, and it has a 50-day moving average of $151.23 and a 200-day moving average of $98.50. The company maintains a strong current ratio of 6.80 and a quick ratio of 6.59, with a debt-to-equity ratio of 29.15.
$RVMD price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Revolution Medicines, Inc.
Recent insider activity at Revolution Medicines includes transactions by CFO Anders Jack, who executed both planned sales and unplanned purchases on June 24, 2026. Jack sold 20,000 shares at an average price of $168.33 under a Rule 10b5-1 plan. On the same day, he also bought 20,000 shares at $18.56 and another 20,000 shares at no cost. Other insiders, including Lorence Kim, Flavia Borellini, and Sushil Patel, each acquired shares on June 18, 2026, without incurring a purchase price.
Analysts Set New Price Targets
On June 29, 2026, Needham maintained its buy rating on Revolution Medicines, setting a price target of $235. Other analysts have also shown optimism. Evercore ISI Group and RBC Capital maintained their buy ratings earlier in June, with respective targets of $220 and $182. The consensus among analysts is a strong buy, with a mean price target of $188.57 based on 21 analyst opinions.
About Revolution Medicines, Inc.
Revolution Medicines, Inc. is a biotechnology company based in Redwood City, California. It focuses on developing targeted therapies for RAS-addicted cancers. The company is known for its RAS(ON) inhibitors, which are designed to be used alone or in combination with other treatments. Revolution Medicines is led by Dr. Mark A. Goldsmith, M.D., Ph.D., and employs around 883 people.
Bottom Line
Investors closely watch Revolution Medicines, Inc. as analysts like Needham reaffirm their confidence in the stock. The repeated buy rating and high price target suggest continued optimism. However, as with all 13F filings and analyst ratings, remember they reflect past assessments and may not indicate current positions or future outcomes.
Get Revolution Medicines, Inc. alerts
New 13F filings, insider trades, and analyst moves on $RVMD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.